Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IL-4 Clear all
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 9, 2026, 6:59 AM EDT
Active, not recruiting Phase 1 Interventional

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

NCT04690595
View directory record Official record
Conditions
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
BAFFR-CAR T cells
Biological
Lead sponsor
PeproMene Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 9, 2026, 6:59 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Dupixent Study for Alternate Administration

NCT06750471
View directory record Official record
Conditions
Nasal Polyps, Sinusitis, Chronic Disease
Interventions
Dupilumab
Biological
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 9, 2026, 6:59 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 9, 2026, 6:59 AM EDT
Recruiting Phase 1 Interventional

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
Interventions
Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 9, 2026, 6:59 AM EDT
Not listed No phase listed Observational

Effect of Montelukast on Basophils, In-vitro

NCT00710450
View directory record Official record
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Mechanisms of Dupilumab in AERD

NCT05031455
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
Aspirin Challenge
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 9, 2026, 6:59 AM EDT
Recruiting Phase 4 Interventional

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

NCT05094570
View directory record Official record
Conditions
Nasal Polyps, Staphylococcus Aureus
Interventions
Dupilumab Prefilled Syringe
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 9, 2026, 6:59 AM EDT
Completed No phase listed Observational

Cytokine Registry Database of Stroke Patients

NCT03297827
View directory record Official record
Conditions
Acute Stroke, Acute Ischemic Stroke, Ischemic Stroke, Hemorrhagic Stroke
Interventions
Serum and Urine measurement of cytokines.
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

NCT00024544
View directory record Official record
Conditions
Asthma
Interventions
anti-IL-4 monoclonal antibody (pascolizumab)
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Los Angeles, California • Mission Viejo, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cold Induced Changes in White Adipose

NCT02596776
View directory record Official record
Conditions
Obese, Normal Body Weight, Prediabetes, Metabolic Syndrome
Interventions
Fat biopsy, Propranolol and fat biopsy, heavy water and fat biopsy
Procedure · Drug · Other
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 9, 2026, 6:59 AM EDT
Completed No phase listed Observational

T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma

NCT00001908
View directory record Official record
Conditions
Asthma, Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

NCT00001564
View directory record Official record
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood

NCT00923910
View directory record Official record
Conditions
Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL)
Interventions
WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4, KLH, WT1 Peptides, Endotoxin, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 74 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 1 Interventional

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

NCT00039052
View directory record Official record
Conditions
Breast Cancer, Kidney Cancer, Lung Cancer
Interventions
interleukin-4 PE38KDEL cytotoxin
Biological
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
2
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 9, 2026, 6:59 AM EDT
Recruiting Phase 1 Interventional

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

NCT05370430
View directory record Official record
Conditions
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Interventions
BAFFR-CAR T cells
Biological
Lead sponsor
PeproMene Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 9, 2026, 6:59 AM EDT
Not listed Phase 1 Interventional

IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

NCT00003842
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
Biological · Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 1 Interventional

A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma

NCT00000769
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interleukin-4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma

NCT00658749
View directory record Official record
Conditions
Asthma
Interventions
AIR645, Physiologic saline solution
Drug
Lead sponsor
Altair Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2009 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Smell Improvement With Dupilumab.

NCT05964465
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Charleston, South Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 9, 2026, 6:59 AM EDT
Terminated Phase 2 Interventional

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00006113
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide, Candida albicans skin test reagent
Biological · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids

NCT05128383
View directory record Official record
Conditions
Keloid
Interventions
Dupilumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 9, 2026, 6:59 AM EDT
Recruiting Phase 2 Interventional

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

NCT06477653
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
dupilumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients

NCT04920916
View directory record Official record
Conditions
COVID-19
Interventions
Dupilumab, Placebo
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 9, 2026, 6:59 AM EDT